Cargando…

A Review of Complement Activation in SLE

PURPOSE OF REVIEW: Complement activation is a key event in the pathogenesis of tissue inflammation and injury in systemic lupus erythematosus (SLE). This review is aimed at comparing the usefulness of measurement of complement proteins in serum/plasma (C3, C4) to complement activation (split) produc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinstein, Arthur, Alexander, Roberta V., Zack, Debra J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Systemic Lupus Erythematosus (G Tsokos, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875837/ https://www.ncbi.nlm.nih.gov/pubmed/33569681 http://dx.doi.org/10.1007/s11926-021-00984-1

Ejemplares similares

Epigenetics in SLE
por: Hedrich, Christian Michael
Publicado: (2017)

The Use of COVID-19 Vaccines in Patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

SARS-CoV-2 and Systemic Lupus Erythematosus
por: Thanou, Aikaterini, et al.
Publicado: (2021)

Systemic Lupus Erythematosus in Children and Young People
por: Charras, A., et al.
Publicado: (2021)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus
por: Falasinnu, Titilola, et al.
Publicado: (2018)

Cell Senescence in Lupus
por: Gao, Lin, et al.
Publicado: (2019)

New Attempts to Define and Clarify Lupus
por: Alarcón-Riquelme, Marta E.
Publicado: (2019)

New Criteria for Lupus
por: Aringer, Martin, et al.
Publicado: (2020)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
por: Panousis, Nikolaos I, et al.
Publicado: (2019)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus
por: Adamichou, Christina, et al.
Publicado: (2021)

Toll‐Like Receptor 9 Deficiency Breaks Tolerance to RNA‐Associated Antigens and Up‐Regulates Toll‐Like Receptor 7 Protein in Sle1 Mice
por: Celhar, Teja, et al.
Publicado: (2018)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia
por: Lewis, Myles J, et al.
Publicado: (2012)

REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)
por: Frangou, Eleni, et al.
Publicado: (2019)

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity
por: Kim, Alfred H. J., et al.
Publicado: (2019)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
por: Azzouz, Doua, et al.
Publicado: (2019)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus
por: Rahman, Saifur, et al.
Publicado: (2019)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Patient Experiences of Systemic Lupus Erythematosus: Findings From a Systematic Review, Meta‐Summary, and Meta‐Synthesis
por: Petrocchi, Valentina, et al.
Publicado: (2022)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares
por: Azzouz, Doua F, et al.
Publicado: (2023)

A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
por: Cheng, Laurence E., et al.
Publicado: (2018)

Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus
por: Odqvist, Lina, et al.
Publicado: (2019)

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020)

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
por: Hoffman, Robert W., et al.
Publicado: (2017)

Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function
por: Meisgen, Sabrina, et al.
Publicado: (2022)

A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation
por: Fox, Bernard J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5psmbdea4qppkr69c8n76h1251